Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer | 5739 | 1491144-00-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 4, 2023 | FDA | IVERIC BIO |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | S01XA32 | SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals |
| FDA EPC | N0000175575 | Complement Inhibitor |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| MeSH PA | D051056 | Complement Inactivating Agents |
| FDA MoA | N0000175974 | Complement Inhibitors |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Geographic atrophy secondary to age-related macular degeneration | indication | 414875008 | |
| Uveitis | contraindication | 128473001 | DOID:13141 |
| Ocular or periocular infection | contraindication | 715266002 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 8236773 | Nov. 11, 2026 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 9617546 | Feb. 14, 2027 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 11273171 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 11491176 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 12016875 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Complement C5 | Secreted | INHIBITOR | Kd | 9.85 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 1613641-69-2 | SECONDARY_CAS_RN |
| CHEBI:760479 | CHEBI |
| CHEMBL6068573 | ChEMBL_ID |
| C000731678 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12857 | IUPHAR_LIGAND_ID |
| DB15165 | DRUGBANK_ID |
| 4042480 | VANDF |
| C5139850 | UMLSCUI |
| CHEMBL4297889 | ChEMBL_ID |
| 10099 | INN_ID |
| 370101 | MMSL |
| 41876 | MMSL |
| 019514 | NDDF |
| 019515 | NDDF |
| D11748 | KEGG_DRUG |
| TT0V5JLG5B | UNII |
| 2645107 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| IZERVAY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82829-002 | INJECTION | 20 mg | INTRAVITREAL | NDA | 26 sections |